To B or not to B the conductor of rheumatoid arthritis orchestra (Q38020364)

27 August 2017

title

To B or not to B the conductor of rheumatoid arthritis orchestra (English)

1 reference

27 August 2017

1 reference

Rita A Moura

1

1 reference

27 August 2017

Luis Graca

series ordinal

2

1 reference

27 August 2017

João E Fonseca

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

1 December 2012

1 reference

Clinical Reviews in Allergy & Immunology

27 August 2017

published in

1 reference

27 August 2017

volume

43

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

281-291

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

27 August 2017

1 reference

Alterations on peripheral blood B-cell subpopulations in very early arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

ON THE OCCURRENCE OF A FACTOR IN HUMAN SERUM ACTIVATING THE SPECIFIC AGGLUTINATION OF SHEEP BLOOD CORPUSCLES

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Correlation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Complement fixation by rheumatoid factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Lymph node genesis is induced by signaling through the lymphotoxin beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Interleukin-6 as a key player in systemic inflammation and joint destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Proinflammatory T helper type 17 cells are effective B-cell helpers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Prevention of arthritis by interleukin 10-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Infiltrations of plasma cells in synovium are highly associated with synovial fluid levels of APRIL in inflamed peripheral joints of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Influence of CD4 or CD8 deficiency on collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Antigen-specific interaction between T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-012-8318-Y

Histology of the synovial tissue: value of semiquantitative analysis for the prediction of joint erosions in rheumatoid arthritis.

21 January 2018

1 reference

12 December 2020

Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint

1 reference

12 December 2020

Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model

1 reference

12 December 2020

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

12 December 2020

B cell-deficient mice do not develop type II collagen-induced arthritis (CIA)

1 reference

12 December 2020

Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction

1 reference

12 December 2020

IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures

1 reference

12 December 2020

Th17 cells can provide B cell help in autoantibody induced arthritis

1 reference

12 December 2020

Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy

1 reference

12 December 2020

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Use of rituximab, the new FDA-approved antibody.

1 reference

12 December 2020

Allergen-specific transforming growth factor-β-producing CD19+CD5+ regulatory B-cell (Br3) responses in human late eczematous allergic reactions to cow's milk

1 reference

12 December 2020

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

1 reference

12 December 2020

T cell activation in rheumatoid synovium is B cell dependent

1 reference

12 December 2020

Lymphoid neogenesis in rheumatoid synovitis

1 reference

12 December 2020

IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells

1 reference

12 December 2020

Variable region gene usage of human monoclonal rheumatoid factors derived from healthy donors following immunization

1 reference

12 December 2020

Organ-specific disease provoked by systemic autoimmunity

1 reference

12 December 2020

IgG rheumatoid factors and self-association of these antibodies

1 reference

12 December 2020

Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation

1 reference

12 December 2020

B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ-line gene usage

1 reference

12 December 2020

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

12 December 2020

Monoclonal anti-CD8 therapy induces disease amelioration in the K/BxN mouse model of spontaneous chronic polyarthritis

1 reference

12 December 2020

B and T Lymphocyte Attenuator Suppresses IL-21 Production from Follicular Th Cells and Subsequent Humoral Immune Responses

1 reference

12 December 2020

The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues

1 reference

12 December 2020

Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers

1 reference

12 December 2020

Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis.

1 reference

12 December 2020

Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium

1 reference

12 December 2020

In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline

1 reference

12 December 2020

Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis

1 reference

12 December 2020

Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse

1 reference

12 December 2020

10.1007/S12016-012-8318-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1013389536

0 references

1 reference